It was a brief 15-minute exchange in the Senate on 2 December last year that exposed the former government's refusal to reveal the over 1,000 medicines impacted by April 2023 'catch-up' reductions and confirmed that they would apply at the brand level to many recently listed products.
The revealing public exchange that should have alarmed the industry
July 29, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News


